Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2019-09-25 Earnings Release
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos start Fase 1-studie met tweede Toledo-compound
Earnings Release Classification · 95% confidence The document is a press release, written in Dutch, announcing the start of a Phase 1 clinical study for a new compound (GLPG3970) related to inflammatory diseases. It details the study design, mentions progress on a related compound (GLPG3312), and provides company background and contact information. This type of announcement, focusing on clinical trial initiation and pipeline progress, is characteristic of an Earnings Release (ER) or a general press release regarding operational updates. Since it is a specific announcement about clinical progress rather than a comprehensive financial report (10-K, IR) or a transcript (CT), and it is not a formal regulatory filing like a DIRS or MRQ, it best fits the 'Earnings Release' category (ER) as it communicates key operational and pipeline milestones, which often accompany or precede formal earnings reports. It is not a Report Publication Announcement (RPA) because it contains substantive news, not just a notice that a report is available. Q3 2019
2019-09-25 Dutch
6-K Filing
Regulatory Filings
2019-09-25 English
Galapagos start Fase 1-studie met tweede Toledo-compound
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV announcing the start of a Phase 1 clinical trial for a new compound (GLPG3970). It provides details on the study, the drug's mechanism, and future expectations. While it contains a link to a PDF version, the text itself is a standalone corporate announcement regarding clinical trial progress, which falls under the category of general regulatory announcements or corporate news updates. Given the specific nature of the announcement (clinical trial initiation), it fits best as a Regulatory Filing (RNS) as it is a standard corporate press release.
2019-09-24 Dutch
Galapagos initiates Phase 1 trial for second Toledo compound
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV announcing the start of a Phase 1 clinical trial for a new drug compound (GLPG3970). It includes company contact information, forward-looking statements, and a link to a PDF attachment. According to the 'Menu vs Meal' rule, documents that announce the release of information or provide links to reports are classified as Report Publication Announcements (RPA).
2019-09-24 English
Galapagos initiates Phase 1 trial for second Toledo compound
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV announcing the start of a Phase 1 clinical trial for a new drug compound (GLPG3970). It includes company contact information, forward-looking statements, and a link to a PDF attachment. According to the 'Menu vs Meal' rule, documents that announce the release of information or provide links to reports are classified as Report Publication Announcements (RPA).
2019-09-24 English
Galapagos start Fase 1-studie met tweede Toledo-compound
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV announcing the start of a Phase 1 clinical trial for a new compound (GLPG3970). It provides details on the study, the drug's mechanism, and future expectations. While it contains a link to a PDF version, the text itself is a standalone corporate announcement regarding clinical trial progress, which falls under the category of general regulatory announcements or corporate news updates. Given the specific nature of the announcement (clinical trial initiation), it fits best as a Regulatory Filing (RNS) as it is a standard corporate press release.
2019-09-24 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.